Complejo Hospitalario de Navarra

The trials here

What the 38 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• Metastatic breast cancer6 trials
• Gastric and oesophageal cancer4 trials
• Bladder cancer3 trials
• Head and neck cancer3 trials
• Colorectal cancer2 trials
• Heart failure2 trials
• Multiple myeloma2 trials
• Obesity2 trials
• Ovarian cancer2 trials
• Pancreatic cancer2 trials
• Ulcerative colitis2 trials
• and 12 more

Phase

• Phase 313 trials
• Phase 210 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed18 trials
• Recruiting11 trials
• Active, not recruiting6 trials
• Not yet recruiting1 trial
• Suspended1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company6 trials
• Fundación GECP2 trials
• Grupo Español de Tratamiento de Tumores de Cabeza y Cuello2 trials
• Hoffmann-La Roche2 trials
• Jazz Pharmaceuticals2 trials
• and 22 more

Running trials

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

  Contact: Nuria Lainez Milagro (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: CRISTINA RODRIGUEZ GUTIERREZ (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: CRISTINA RODRIGUEZ GUTIERREZ (principal investigator)

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Maite Martinez Aguillo (principal investigator)

• Recruiting

  A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Phase 2· Jazz Pharmaceuticals· Source

  Contact: Clinical Trial Disclosure & Transparency

• Recruiting

  Multicenter Trial of Proximal Femoral Guided Growth in Children With CP and Hips at Risk of Dislocation (GGSH-MC)

  NCT06956729· Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús· Source

  Contact: JULIO DUART, M.D.

• Active, not recruiting

  Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

  NCT05784012· Phase 1/2· Grupo Español de Tratamiento de Tumores de Cabeza y Cuello· Source

• Recruiting

  Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

  NCT06055504· Consorcio Centro de Investigación Biomédica en Red (CIBER)· Source

  Contact: Maria Teresa Basurte Elorz (principal investigator)

• Recruiting

  High Definition Medicine for Solid Tumors Oncology

  NCT06590506· Centro Nacional de Investigaciones Oncologicas CARLOS III· Source

  Contact: Ruth Vera, PhD

• Recruiting

  NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

  NCT05558319· Phase 3· PETHEMA Foundation· Source

  Contact: Jose María Arguiñano Pérez, Dr

• Active, not recruiting

  Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

  NCT05382052· Fundación GECP· Source

• Active, not recruiting

  Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

  NCT05169567· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

  NCT05152147· Phase 3· Jazz Pharmaceuticals· Source

• Active, not recruiting

  Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

  NCT03742297· Phase 3· PETHEMA Foundation· Source

• Active, not recruiting

  Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

  NCT03605771· Grupo Español Multidisciplinar de Melanoma· Source

• Recruiting

  A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

  NCT02819882· Spanish Breast Cancer Research Group· Source

  Contact: MS Study Project Manager

• Recruiting

  Thoracic Tumours Register

  NCT02941458· Spanish Lung Cancer Group· Source

  Contact: Berta Hernández, MD

• Recruiting

  Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

  NCT01574053· CHDI Foundation, Inc.· Source

  Contact: Ana Carmona Rueda

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Bladder cancer2 recruiting
• Obesity2 recruiting
• Cerebral palsy1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Dilated cardiomyopathy1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Huntington's disease1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source

• Completed

  Therapeutic Effect of PBF-680 in Patients With COPD

  NCT05262218· Phase 2· Palobiofarma SL· Source

• Completed

  Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

  NCT04813627· BioNTech SE· Source

• Completed

  A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

  NCT04785820· Phase 2· Hoffmann-La Roche· Source

• Completed

  ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

  NCT04603183· Phase 2· MedSIR· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Terminated

  Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

  NCT04512430· Phase 2· Fundación GECP· Source

• Completed

  Follow-up in Early and Locally Advanced Breast Cancer Patients

  NCT03859453· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Completed

  First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

  NCT04408118· Phase 2· MedSIR· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

  NCT04282109· Phase 2· Grupo Español de Tratamiento de Tumores de Cabeza y Cuello· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

  NCT03596385· Phase 4· Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

  NCT02448420· Phase 2· SOLTI Breast Cancer Research Group· Source

• Completed

  An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

  NCT01853826· Phase 3· Boehringer Ingelheim· Source